In May 2023, the U.S. Government Accountability Office published a survey on the prevalence and impact of non-compete ...

Following back-to-back approvals in lymphocytic leukemia, Bristol Myers Squibb’s CAR-T therapy Breyanzi on Wednesday won the ...

In Tuesday’s first-quarter 2024 financial results, Bayer reported a slight drop in sales amid its sweeping companywide ...

Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma ...

GSK said Thursday it plans to divest its remaining 4.2% stake in the consumer health spinout, its fourth and final round of ...

A Senate health committee report published Wednesday forecasts spending on prescription drugs may hit $1 trillion a year in ...

Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary ...

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

With Monday’s agreement, AbbVie joins the industry’s growing interest in psychedelic therapies and looks to leverage ...

Following an initial rejection in 2023, Ascendis Pharma on Tuesday said it faces another regulatory bump in the road for ...

Applications of the technology range from data collection to drug design to raising the alarm on product safety, but its ...